Pfizer Stock News

If you're a long-term investor, why should you be paying closer attention to pharmaceutical giant Pfizer (PFE -3.98%)? Because of its dividend, of course!

Shares in Pfizer and Moderna fell 3.9% and 7.4%, respectively.

Sixteen of the thirty-eight highest-yield, 'safer' S&P 500 dividend stocks are highlighted as ready to buy, with adequate free cash flow supporting payouts. Analyst forecasts suggest top ten S&P 500 dividend 'dogs' could deliver 20.45% to 38.5% net gains by September 2026, with an average gain of 27.35%. Stocks like Amcor, Healthpeak, Conagra, Pfizer, and Verizon offer the best combination of h...

Shares of companies that make COVID vaccines sank Friday, after a report raised fears that Trump administration health officials will blame the vaccines for some child deaths.

Shares of Pfizer and Moderna fell on Friday after a report that Trump administration health officials plan to link Covid vaccines to the deaths of 25 children.  The report comes as Health and Human Services Secretary Robert F.

Pfizer achieved 10% year-over-year Q2 2025 revenue growth to $14.7 billion, driven by Abrysvo RSV vaccine and Seagen-acquired oncology assets. Management expects over $20 billion in risk-adjusted revenue from new launches by 2030, offsetting $17–$20 billion in patent expirations. R&D investment of ~$11 billion in 2025 supports 28 Phase 3 programs across oncology, vaccines, inflammation, and rar...

The effort falls well short of banning the ads outright, but could dent sales.

Pfizer Inc. crushed Q2 estimates with a 36% EPS beat, proving its operational turnaround is gaining momentum despite negative market sentiment and recent stock underperformance. Aggressive cost-cutting, targeting $7.7 billion in savings, is driving massive operating leverage and led PFE management to raise its full-year 2025 EPS guidance. Pfizer is successfully pivoting from COVID dependence. I...